Skip to main content
Biocartis Group NV logo

Biocartis Group NV — Investor Relations & Filings

Ticker · BCART ISIN · BE0974281132 LEI · 549300J4HOJL5KG8HY54 BR Manufacturing
Open in API
Filings indexed 636 across all filing types
Latest filing 2019-10-04 Major Shareholding Noti…
Country BE Belgium
Listing BR BCART

About Biocartis Group NV

https://www.biocartis.com/en

Biocartis Group NV is a molecular diagnostics company that develops and commercializes its proprietary Idylla™ platform. This fully automated, sample-to-result system is designed to provide fast, easy, and actionable molecular diagnostic results, making advanced testing accessible to laboratories of any size. The company's primary focus is in the field of oncology, offering a menu of tests that support the diagnosis and treatment of various cancers, including lung, colorectal, melanoma, and breast cancer. Biocartis aims to enable personalized medicine for patients by providing universal access to molecular testing. The company also collaborates with pharmaceutical partners in the development of companion diagnostics.

Recent filings

Filing Released Lang Actions
Persbericht Biocartis Group NV: Openbaarmaking van een transparantiekennisgeving
Major Shareholding Notification Classification · 98% confidence The document is a press release ('PERSBERICHT: GEREGLEMENTEERDE INFORMATIE') dated October 4, 2019, announcing that the company received a transparency notification ('transparantiekennisgeving') regarding a change in significant shareholding. Specifically, it details that Debiopharm Innovation Fund S.A.'s stake dropped below the 5% threshold, citing the Belgian Transparency Law. This content directly corresponds to the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds.
2019-10-04 Dutch
191004 Notification Form Debiopharm.pdf
Major Shareholding Notification Classification · 98% confidence The document is clearly identified as 'Form TR-1 BE' and contains a 'Transparency notification' regarding the 'Acquisition or disposal of voting securities or voting rights'. It details changes in share ownership thresholds (crossing 5%) by specific persons/entities (Debiopharm Innovation Fund S.A., Après-demain Holding S.A., Thierry Mauvernay) in an issuer (BIOCARTIS). This type of filing, which reports changes in significant shareholdings, directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is a regulatory form, MRQ is more specific than the general 'RNS' fallback.
2019-10-04 English
191003_PR_TranspNotif_Debio_ENG_FINAL.pdf
Director's Dealing Classification · 98% confidence The document is explicitly titled 'PRESS RELEASE REGULATED INFORMATION' and announces the 'Disclosure of a transparency notification' regarding a change in major shareholdings (Debiopharm Innovation Fund S.A. falling below the 5% threshold). This directly relates to notifications concerning changes in significant share ownership levels, which corresponds to the Major Shareholding Notification category (MRQ). Although it is a press release, the core content is the notification itself, not just an announcement of a report's publication (RPA) or a general regulatory filing (RNS). The content details the transaction date, threshold crossed, and resulting holding percentage.
2019-10-04 English
191003_PR_TranspNotif_Debio_NL_FINAL.pdf
Director's Dealing Classification · 98% confidence The document is titled "Openbaarmaking van een transparantiekennisgeving" (Disclosure of a transparency notification) and explicitly states it is announcing the receipt of a notification regarding a change in shareholding percentage falling below the 5% threshold, as required by the Belgian Transparency Law. This directly relates to changes in significant share ownership levels. The filing type that matches this description is 'Major Shareholding Notification' (MRQ). Although it is presented as a press release, the core content is the mandatory disclosure of a change in ownership threshold crossing.
2019-10-04 Dutch
Press news Biocartis Group: Resultaten van de Bijzondere Algemene Aandeelhoudersvergadering gehouden op 27 september 2019
AGM Information Classification · 98% confidence The document is a press release announcing the results of an Extraordinary General Meeting (EGM) held by Biocartis Group NV. It explicitly states the outcome of the shareholder vote regarding agenda items. While it mentions the meeting, it is a formal declaration of the voting results rather than the full proxy materials or the meeting presentation itself. Therefore, it falls under the category of Declaration of Voting Results & Voting Rights Announcements.
2019-09-27 Dutch
Press news Biocartis Group: Results of the Special Shareholders’ Meeting held on 27 September 2019
AGM Information Classification · 99% confidence The document is explicitly titled 'PRESS RELEASE: REGULATED INFORMATION' and announces the 'Results of the Special Shareholders’ Meeting held on 27 September 2019'. It details the approval of a sole agenda item related to convertible bonds. This content directly relates to the outcomes of a shareholder meeting. While it is a press release, the core subject matter is the result of a vote at a general meeting, which aligns best with the 'Declaration of Voting Results & Voting Rights Announcements' (DVA). It is not a general AGM presentation (AGM-R), nor is it a proxy solicitation document (PSI). Since it reports the definitive results of a vote, DVA is the most specific fit.
2019-09-27 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.